# Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL

> **NCT00881920** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 54 (estimated)

## Conditions studied

- Lymphoma
- Myeloma
- Leukemia

## Interventions

- **BIOLOGICAL:** Kappa CD28 T cells

## Key facts

- **NCT ID:** NCT00881920
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-07
- **Primary completion:** 2018-07
- **Final completion:** 2035-07
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-10-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00881920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00881920, "Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00881920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*